Dihydroberberine exhibits synergistic effects with sunitinib on NSCLC NCI‐H460 cells by repressing MAP kinase pathways and inflammatory mediators

Highly effective and attenuated dose schedules are good regimens for drug research and development. Combination chemotherapy is a good strategy in cancer therapy. We evaluated the antitumour effects of dihydroberberine combined with sunitinib (DCS) on the human non‐small cell lung cancer cell lines...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Bingling, Ma, Yujiao, Wang, Wenjie, Zhan, Yingzhuan, Zhang, Dongdong, Liu, Rui, Zhang, Yanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618684/
https://www.ncbi.nlm.nih.gov/pubmed/28444871
http://dx.doi.org/10.1111/jcmm.13178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618684/
https://www.ncbi.nlm.nih.gov/pubmed/28444871
http://dx.doi.org/10.1111/jcmm.13178

Ejemplares similares